Control Bionics and Numotion partnership will expand access those who can benefit from Control Bionics’ customized Augmentative and Alternative Communication (AAC) solutions.
Control Bionics‘ products help individuals dealing with a wide range of diagnoses, including ALS/MND, spinal muscular atrophy, cerebral palsy, and spinal cord injury. The Trilogy product line is a best-in-class option in the wider category of AAC devices, offering a customizable solution that complements a patient’s abilities as needs change over time alongside industry leading customer support.
“Control Bionics is passionate about helping clients find their ‘voice’ and regain control of their lives,” explained Neale Java, CFO at Control Bionics. “We’re excited to be partnering with Numotion, an established company within the CRT space, to expand access to our life-changing, multi-modal communication solutions throughout the Northeast.”
While Numotion has more than 150 US locations, this partnership will be focused within the states of New Hampshire, Vermont, and New York to increase market awareness of the Control Bionics Trilogy Speech Generating Device as well as its best in class NeuroNode 3.0 sEMG (Electromyography) + Spatial sensor. This agreement is in line with Control Bionics’ growth strategy to access the larger rehab market and reinforces its commitment to provide industry-leading solutions with access to all.
“Adding Control Bionics’ Trilogy product line to our offering of AAC devices allows us to better serve those looking for flexible access methods and multi-modal solutions,” said Amanda Whipple, Director of Augmentative Communication at Numotion.”Their unique approach to AAC devices matches our desire to consistently improve and expand our offerings with cutting edge technology, ultimately offering the greatest benefit to our customers in need.”
Appointments are now available to begin the assessment process for Control Bionics’ products. Both Control Bionics and Numotion offer and support an extensive loan library of devices for clients and their clinicians wishing to trial this latest solution.